English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 55542/89862 (62%)
造訪人次 : 11006275      線上人數 : 31
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: http://tkuir.lib.tku.edu.tw:8080/dspace/handle/987654321/93116


    題名: Add-on Treatment of Benzoate for Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial of d-Amino Acid Oxidase Inhibitor
    作者: Lane, Hsien-Yuan;Lin, Ching-Hua;Michael F. Green;Gerhard Hellemann;Huang, Chih-Chia;Chen, Po-Wei;Tun, Rene;Chang, Yue-Cung;Tsai, Guochuan E.
    貢獻者: 淡江大學數學學系
    日期: 2013-12-01
    上傳時間: 2013-11-21 16:29:27 (UTC+8)
    出版者: Chicago: American Medical Association
    摘要: Importance In addition to dopaminergic hyperactivity, hypofunction of the N-methyl-d-aspartate receptor (NMDAR) has an important role in the pathophysiology of schizophrenia. Enhancing NMDAR-mediated neurotransmission is considered a novel treatment approach. To date, several trials on adjuvant NMDA-enhancing agents have revealed beneficial, but limited, efficacy for positive and negative symptoms and cognition. Another method to enhance NMDA function is to raise the levels of d-amino acids by blocking their metabolism. Sodium benzoate is a d-amino acid oxidase inhibitor.

    Objective To examine the clinical and cognitive efficacy and safety of add-on treatment of sodium benzoate for schizophrenia.

    Design, Setting, and Participants A randomized, double-blind, placebo-controlled trial in 2 major medical centers in Taiwan composed of 52 patients with chronic schizophrenia who had been stabilized with antipsychotic medications for 3 months or longer.

    Interventions Six weeks of add-on treatment of 1 g/d of sodium benzoate or placebo.

    Main Outcomes and Measures The primary outcome measure was the Positive and Negative Syndrome Scale (PANSS) total score. Clinical efficacy and adverse effects were assessed biweekly. Cognitive functions were measured before and after the add-on treatment.

    Results Benzoate produced a 21% improvement in PANSS total score and large effect sizes (range, 1.16-1.69) in the PANSS total and subscales, Scales for the Assessment of Negative Symptoms–20 items, Global Assessment of Function, Quality of Life Scale and Clinical Global Impression and improvement in the neurocognition subtests as recommended by the National Institute of Mental Health’s Measurement and Treatment Research to Improve Cognition in Schizophrenia initiative, including the domains of processing speed and visual learning. Benzoate was well tolerated without significant adverse effects.

    Conclusions and Relevance Benzoate adjunctive therapy significantly improved a variety of symptom domains and neurocognition in patients with chronic schizophrenia. The preliminary results show promise for d-amino acid oxidase inhibition as a novel approach for new drug development for schizophrenia.
    關聯: JAMA Psychiatry 70(12), pp.1267-1275
    DOI: 10.1001/jamapsychiatry.2013.2159
    顯示於類別:[數學學系暨研究所] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML23檢視/開啟

    在機構典藏中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - 回饋